Literature DB >> 25301676

Quantification of piperacillin, tazobactam, cefepime, meropenem, ciprofloxacin and linezolid in serum using an isotope dilution UHPLC-MS/MS method with semi-automated sample preparation.

Johannes Zander, Barbara Maier, Anna Suhr, Michael Zoller, Lorenz Frey, Daniel Teupser, Michael Vogeser.   

Abstract

BACKGROUND: Recent studies have demonstrated highly variable blood concentrations of piperacillin, tazobactam, cefepime, meropenem, ciprofloxacin and linezolid in critically ill patients with a high incidence of sub-therapeutic levels. Consequently, therapeutic drug monitoring (TDM) of these antibiotics has to be considered, requiring robust and reliable routine analytical methods. The aim of the present work was to develop and validate a multi-analyte ultra high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) method for the simultaneous quantification of the above mentioned antibiotics.
METHODS: Sample preparation included a manual protein precipitation step followed by two-dimensional ultra high performance liquid chromatography (2D-UHPLC). Corresponding stable isotope-labeled substances were used as internal standards for all of the analytes, with the exception of tazobactam. The injected sample volume was 7 μL. The run time was 5.0 min.
RESULTS: Inaccuracy was ≤8% and imprecision coefficient of variation (CV) was <9% for all analytes. Only minor matrix effects and negligible carry-over was observed. The method was found to be robust during the validation period.
CONCLUSIONS: We were able to develop a reliable 2D-UHPLC-MS/MS method addressing analytes with highly heterogeneous physico-chemical properties. The novel assay may be an efficient tool for an optimized process workflow in clinical laboratories for important antibiotics in regards to TDM.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25301676     DOI: 10.1515/cclm-2014-0746

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  10 in total

1.  Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses.

Authors:  Carina Schuster; Sebastian Sterz; Daniel Teupser; Mathias Brügel; Michael Vogeser; Michael Paal
Journal:  J Vis Exp       Date:  2018-08-30       Impact factor: 1.355

2.  Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 1: Assay Development and Validation.

Authors:  Ronilda D'Cunha; Thanh Bach; Beth Ann Young; Peizhi Li; Demet Nalbant; Jun Zhang; Patricia Winokur; Guohua An
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

3.  Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 2: Stability Evaluation.

Authors:  Ronilda D'Cunha; Thanh Bach; Beth Ann Young; Peizhi Li; Demet Nalbant; Jun Zhang; Patricia Winokur; Guohua An
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

Review 4.  Clinical Pharmacokinetics and Pharmacodynamics of Cefepime.

Authors:  Gwendolyn M Pais; Jack Chang; Erin F Barreto; Gideon Stitt; Kevin J Downes; Mohammad H Alshaer; Emily Lesnicki; Vaidehi Panchal; Maria Bruzzone; Argyle V Bumanglag; Sara N Burke; Marc H Scheetz
Journal:  Clin Pharmacokinet       Date:  2022-06-29       Impact factor: 5.577

5.  Development and validation of a volumetric absorptive microsampling- liquid chromatography mass spectrometry method for the analysis of cefepime in human whole blood: Application to pediatric pharmacokinetic study.

Authors:  Ganesh S Moorthy; Christina Vedar; Nicole R Zane; Kevin J Downes; Janice L Prodell; Mary Ann DiLiberto; Athena F Zuppa
Journal:  J Pharm Biomed Anal       Date:  2019-11-20       Impact factor: 3.935

6.  Target Site Pharmacokinetics of Meropenem: Measurement in Human Explanted Lung Tissue by Bronchoalveolar Lavage, Microdialysis, and Homogenized Lung Tissue.

Authors:  Michael Paal; Christina Scharf; Ann Katrin Denninger; Luis Ilia; Charlotte Kloft; Nikolaus Kneidinger; Uwe Liebchen; Sebastian Michel; Christian Schneider; Sebastian Schröpf; Carina Schuster; Michael Vogeser; Ferdinand Weinelt; Johannes Zander; Michael Zoller; Ines Schroeder
Journal:  Antimicrob Agents Chemother       Date:  2021-09-27       Impact factor: 5.191

7.  UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays.

Authors:  Joachim Kuhn; Tatjana Gripp; Tobias Flieder; Marcus Dittrich; Doris Hendig; Jessica Busse; Cornelius Knabbe; Ingvild Birschmann
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

8.  FT-IR/ATR Solid Film Formation: Qualitative and Quantitative Analysis of a Piperacillin-Tazobactam Formulation.

Authors:  Ioanna Chrisikou; Malvina Orkoula; Christos Kontoyannis
Journal:  Molecules       Date:  2020-12-21       Impact factor: 4.411

9.  Piperacillin concentration in relation to therapeutic range in critically ill patients--a prospective observational study.

Authors:  Johannes Zander; Gundula Döbbeler; Dorothea Nagel; Barbara Maier; Christina Scharf; Mikayil Huseyn-Zada; Jette Jung; Lorenz Frey; Michael Vogeser; Michael Zoller
Journal:  Crit Care       Date:  2016-04-04       Impact factor: 9.097

10.  Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.

Authors:  Lisa Ehmann; Michael Zoller; Iris K Minichmayr; Christina Scharf; Barbara Maier; Maximilian V Schmitt; Niklas Hartung; Wilhelm Huisinga; Michael Vogeser; Lorenz Frey; Johannes Zander; Charlotte Kloft
Journal:  Crit Care       Date:  2017-10-21       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.